imusyn
Biotechnology company (founded 2001) providing recombinant proteins, reagents and services for transfusion medicine, immunology and diagnostic development. Capabilities include design and production of recombinant HLA and blood-group antigens, T cell staining reagents, antibody fragment-based reagents to mitigate therapeutic-antibody interference in serological testing, high-throughput peptide–MHC binding analysis, and support for IVD design, clinical evaluation and regulatory conformity. Operates integrated R&D, QC and recombinant protein production facilities and maintains a quality management system certified to EN ISO 13485:2016.
Industries
Nr. of Employees
small (1-50)
Patents
Analysis of anti-erythrocyte antibody in the presence of antibody directed against a surface-bound erythrocyte antigen
US-11131678-B2
View Details
Analysis of anti-erythrocyte antibody in the presence of antibody directed against a surface-bound erythrocyte antigen
US-11131678-B2
View DetailsProducts
Recombinant HLA class I and class II proteins (RUO)
Soluble, truncated recombinant HLA antigens produced in mammalian cell culture with QC by electrophoresis, ELISA and antiserum reactivity testing, intended for research use.
Peptide–MHC multimer reagents for T cell staining (RUO)
Pre-multimerized fluorophore-labeled peptide–MHC reagents and loadable peptide-receptive variants for detection and quantification of antigen‑specific T cells by flow cytometry (research use only).
Recombinant blood group antigen preparations (RUO)
Recombinant blood group antigens for use in inhibition and identification workflows in serology, validated for compatibility with common gel-card systems (research use only).
CD38-masking reagent for mitigation of therapeutic-antibody interference (IVD)
Antibody-fragment-based reagent formulated to mask CD38 on test red blood cells to inhibit agglutination caused by therapeutic anti-CD38 antibodies in IAT; supplied with validated protocols and process control guidance (IVD use).
Monoclonal antibodies for research use
Panel of monoclonal antibodies supplied for laboratory research applications.
Recombinant HLA class I and class II proteins (RUO)
Soluble, truncated recombinant HLA antigens produced in mammalian cell culture with QC by electrophoresis, ELISA and antiserum reactivity testing, intended for research use.
Peptide–MHC multimer reagents for T cell staining (RUO)
Pre-multimerized fluorophore-labeled peptide–MHC reagents and loadable peptide-receptive variants for detection and quantification of antigen‑specific T cells by flow cytometry (research use only).
Recombinant blood group antigen preparations (RUO)
Recombinant blood group antigens for use in inhibition and identification workflows in serology, validated for compatibility with common gel-card systems (research use only).
CD38-masking reagent for mitigation of therapeutic-antibody interference (IVD)
Antibody-fragment-based reagent formulated to mask CD38 on test red blood cells to inhibit agglutination caused by therapeutic anti-CD38 antibodies in IAT; supplied with validated protocols and process control guidance (IVD use).
Monoclonal antibodies for research use
Panel of monoclonal antibodies supplied for laboratory research applications.
Services
Assessment of peptide binding and stability to MHC/HLA complexes for epitope identification in vaccine and immuno-oncology research.
Consulting on regulatory requirements, clinical evaluation planning, technical file preparation and steps toward CE marking for in‑vitro diagnostic products.
Protein and antigen design services for assay creation, including engineering of antigens and development of reagent prototypes for diagnostic applications.
Contract manufacturing of recombinant proteins and reagents with quality controls aligned to EN ISO 13485:2016 processes.
Development of instructions for use, standard operating procedures, troubleshooting guidance and analytical compatibility testing for gel-card based serology workflows.
Assessment of peptide binding and stability to MHC/HLA complexes for epitope identification in vaccine and immuno-oncology research.
Consulting on regulatory requirements, clinical evaluation planning, technical file preparation and steps toward CE marking for in‑vitro diagnostic products.
Protein and antigen design services for assay creation, including engineering of antigens and development of reagent prototypes for diagnostic applications.
Contract manufacturing of recombinant proteins and reagents with quality controls aligned to EN ISO 13485:2016 processes.
Development of instructions for use, standard operating procedures, troubleshooting guidance and analytical compatibility testing for gel-card based serology workflows.
Expertise Areas
- Recombinant protein engineering and biomanufacturing
- Transfusion-medicine reagents and serology workflows (IAT)
- T cell assay development and peptide–MHC multimer technology
- High-throughput peptide–MHC binding analysis
Key Technologies
- Mammalian and bacterial recombinant expression systems
- Automated protein purification and chromatography
- Antibody-fragment-based antigen masking reagents
- Peptide–MHC multimer production
News & Updates
Peer-reviewed studies cited describing reagents and methods to mitigate interference of therapeutic anti-CD38 monoclonal antibodies in pre‑transfusion serological testing.
Quality management system certificate for design, development, manufacture and distribution of HLA typing reagents, recombinant blood group antigens and antibody fragment reagents.
Certificate documenting conformity with the EU IVD Directive for relevant products.
Internal clinical performance evaluation reporting 86.5% complete inhibition rate in the evaluated cohort; comparative data versus DTT treatment also reported.
Peer-reviewed studies cited describing reagents and methods to mitigate interference of therapeutic anti-CD38 monoclonal antibodies in pre‑transfusion serological testing.
Quality management system certificate for design, development, manufacture and distribution of HLA typing reagents, recombinant blood group antigens and antibody fragment reagents.
Certificate documenting conformity with the EU IVD Directive for relevant products.
Internal clinical performance evaluation reporting 86.5% complete inhibition rate in the evaluated cohort; comparative data versus DTT treatment also reported.